journal article·2022-07-11Open access

Antibacterial activity of a berberine nanoformulation

Hue Thi Nguyen, Tuyet Nhung Pham, Anh-Tuan Le, Nguyen Thanh Thuy, Tran Quang Huy, Thuy Thi Thu Nguyen

Abstract

This study describes the preparation of berberine (BBR) in nanoformulation to enhance its solubility and increase its antibacterial effectiveness against hospital-acquired infections. BBR nanoparticles (BBR NPs) were formed by antisolvent precipitation (ASP) using glycerol as a safe organic solvent. UV–vis absorption spectra demonstrated that the solubility of BBR NPs was greatly enhanced compared to that of pure BBR. Glycerol played a role as a stabilizer for BBR NPs through the formation of hydrogen bonds between glycerol and BBR NPs. The prepared BBR NPs have a narrow size distribution with an average diameter of 156 nm at a concentration of 2.0 mg/mL, measured by dynamic light scattering. After nanoformulation, the concentration of BBR NPs could reach up to 5.0 mg/mL, which is much higher than the saturation concentration without treatment. Results show a strongly enhanced antibacterial activity of BBR NPs compared with that of pure BBR at the same concentration. The minimum bactericidal concentration of BBR NPs against methicillin-resistant Staphylococcus aureus and Escherichia coli O157:H7 was found to be 2.0 and 5.0 mg/mL, respectively. Transmission electron microscopy showed that BBR NPs surrounded the bacterial cells and severely damaged the cell walls. Therefore, BBR NPs prepared by ASP appear to be a potential candidate for the treatment of bacterial pathogens.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Berberine and alkaloids research · Antibiotic Resistance in Bacteria · Alkaloids: synthesis and pharmacology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (45)

Show source-provided references
1. 10.14715/cmb/2018.64.8.510.14715/cmb/2018.64.8.5 ↗
2. 10.1002/ptr.239910.1002/ptr.2399 ↗
3. 10.1016/j.micpath.2020.10454210.1016/j.micpath.2020.104542 ↗
4. 10.1186/s12906-019-2558-910.1186/s12906-019-2558-9 ↗
5. 10.1186/s40249-021-00812-910.1186/s40249-021-00812-9 ↗
6. 10.1186/s13568-020-01088-210.1186/s13568-020-01088-2 ↗
7. 10.1016/j.canlet.2003.09.00210.1016/j.canlet.2003.09.002 ↗
8. 10.1186/0717-6287-47-810.1186/0717-6287-47-8 ↗
9. 10.1155/2016/875343610.1155/2016/8753436 ↗
10. 10.1016/j.bmcl.2019.12670910.1016/j.bmcl.2019.126709 ↗
11. 10.3389/fmolb.2020.62449410.3389/fmolb.2020.624494 ↗
12. 10.3389/fmicb.2019.0258410.3389/fmicb.2019.02584 ↗
13. 10.1016/j.actbio.2010.08.02810.1016/j.actbio.2010.08.028 ↗
14. 10.1089/jmf.2005.8.45410.1089/jmf.2005.8.454 ↗
15. Peng · International Journal of Clinical and Experimental Pathology · 2015 · 8 · 5217
16. 10.1038/srep2474810.1038/srep24748 ↗
17. 10.1016/j.bmcl.2006.12.08510.1016/j.bmcl.2006.12.085 ↗
18. 10.1186/s12985-016-0674-410.1186/s12985-016-0674-4 ↗
19. 10.1002/ptr.619610.1002/ptr.6196 ↗
20. 10.1007/s00705-020-04706-310.1007/s00705-020-04706-3 ↗
21. 10.3390/v1302028210.3390/v13020282 ↗
22. 10.1016/j.phyplu.2022.10025210.1016/j.phyplu.2022.100252 ↗
23. 10.3390/v1312243710.3390/v13122437 ↗
24. 10.1080/07391102.2020.172456810.1080/07391102.2020.1724568 ↗
25. 10.1016/j.sjbs.2020.10.00610.1016/j.sjbs.2020.10.006 ↗
26. 10.2147/dddt.s15612310.2147/dddt.s156123 ↗
27. 10.1016/j.jconrel.2008.03.00210.1016/j.jconrel.2008.03.002 ↗
28. 10.1016/j.ijpharm.2009.09.03010.1016/j.ijpharm.2009.09.030 ↗
29. 10.1080/10717544.2017.132106210.1080/10717544.2017.1321062 ↗
30. 10.1016/j.ijpharm.2017.04.07310.1016/j.ijpharm.2017.04.073 ↗
31. 10.1016/j.biopha.2018.05.06710.1016/j.biopha.2018.05.067 ↗
32. 10.1002/cplu.20200049610.1002/cplu.202000496 ↗
33. 10.1021/acsomega.0c0159210.1021/acsomega.0c01592 ↗
34. 10.1517/17425247.2014.91356810.1517/17425247.2014.913568 ↗
35. 10.1107/s205322961901543210.1107/s2053229619015432 ↗
36. 10.1016/j.saa.2017.05.07010.1016/j.saa.2017.05.070 ↗
37. 10.1208/s12249-010-9520-y10.1208/s12249-010-9520-y ↗
38. 10.1021/acs.jchemed.5b0101410.1021/acs.jchemed.5b01014 ↗
39. 10.7763/ijcea.2013.v4.32110.7763/ijcea.2013.v4.321 ↗
40. 10.1007/bf0150820910.1007/bf01508209 ↗
41. 10.1099/jmm.0.00010610.1099/jmm.0.000106 ↗
42. 10.1016/j.micpath.2016.11.01110.1016/j.micpath.2016.11.011 ↗
43. 10.3389/fmicb.2020.0062110.3389/fmicb.2020.00621 ↗
44. 10.1039/d0ra07573f10.1039/d0ra07573f ↗
45. 10.1007/s11664-017-5315-110.1007/s11664-017-5315-1 ↗